Astrazeneca (AZN) Receivables - Other (2009 - 2026)

Astrazeneca has reported Receivables - Other for 18 years, with the latest figure at $1.4 billion in Q2 2026.

• On a quarterly basis, Receivables - Other rose 26.74% year-over-year to $1.4 billion in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 26.74% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 42.69% from the prior year.
• Receivables - Other was $1.4 billion for Q2 2026 at Astrazeneca, up from $1.2 billion in the prior quarter.
• The five-year high for Receivables - Other was $1.4 billion in Q2 2026, with the low at $682.0 million in Q1 2023.
• Average Receivables - Other over 5 years is $932.3 million, with a median of $872.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other jumped 57.38% in 2022, then dropped 21.06% in 2023.
• Over 5 years, Receivables - Other stood at $835.0 million in 2022, then fell by 3.83% to $803.0 million in 2023, then advanced by 15.82% to $930.0 million in 2024, then jumped by 42.69% to $1.3 billion in 2025, then rose by 1.81% to $1.4 billion in 2026.
• The last three Receivables - Other figures came in at $1.4 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.